FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3166128844> ?p ?o ?g. }

• W3166128844 endingPage "e21135" @default.
• W3166128844 startingPage "e21135" @default.
• W3166128844 abstract "e21135 Background: There is an unmet need for reliable biomarkers predictive of treatment outcome with immunotherapy in patients with non-small cell lung cancer (NSCLC). The aim of our study is to examine, in front-line patients, the potential utility of a proteomic signature, PIR (primary immune response), developed and validated in 2 nd line patients (M. Muller Clin Cancer Res. 2020 Oct 1;26(19):5188-5197. doi: 10.1158/1078-0432.CCR-20-0538. Epub 2020 Jul 6) as a predictive biomarker of response to treatment with pembrolizumab in a first-line setting. Methods: Pretreatment serum samples were collected from stage IV NSCLC patients treated with a pembrolizumab-containing regimen in first-line at the Netherlands Cancer Institute and Erasmus Medical Center between 2016 and 2020. Data on demographics, ECOG performance status (PS), PD-L1 expression, treatment, progression free survival (PFS) and overall survival (OS) were collected. The PIR test was performed and classified in two groups: resistant vs. intermediate/sensitive (not-resistant). Results: Serum samples of 119 patients were available for analysis. Median age was 65 (36-82) years; 49% female; PS 0-1 80%. 45 samples failed QC and were excluded allowing for the analysis of 74 patients: 24 receiving pembrolizumab monotherapy, and 50 receiving a combination of chemotherapy and pembrolizumab. Overall, median PFS was 5.3 months in the resistant group vs. 9.0 months in the not-resistant group (HR 0.60 (95%CI 0.33-1.08; p = 0.09). In patients receiving pembrolizumab monotherapy, the resistant group had a trend toward shorter PFS (median PFS 3.4 months vs. 10.3 months) then the non-resistant group, (HR 0.42 (95% CI 0.15-1.21; p = 0.11))). No difference was observed in patients treated with a combination of chemotherapy and pembrolizumab (median PFS 5.8 months vs. 9.0 months, respectively; HR = 0.65 (95% CI 0.31-1.36; p = 0.25). Median OS was not reached vs 17.0 months, respectively (HR 0.90 (95% CI 0.34-2.36; p = 0.83)). We did not observe any significant association between performance score and PD-L1 expression, and the PIR test. Conclusions: These data encourage further study of PIR as a predictive biomarker for first-line treatment with pembrolizumab in NSCLC patients." @default.
• W3166128844 created "2021-06-22" @default.
• W3166128844 creator A5006585307 @default.
• W3166128844 creator A5045006845 @default.
• W3166128844 creator A5064053465 @default.
• W3166128844 creator A5070454355 @default.
• W3166128844 creator A5072346965 @default.
• W3166128844 creator A5073885025 @default.
• W3166128844 creator A5089042997 @default.
• W3166128844 date "2021-05-20" @default.
• W3166128844 modified "2023-10-03" @default.
• W3166128844 title "Retrospective validation of a pretreatment serum protein profile in metastatic non-small cell lung cancer patients treated with a pembrolizumab containing regime as first line of treatment." @default.
• W3166128844 doi "https://doi.org/10.1200/jco.2021.39.15_suppl.e21135" @default.
• W3166128844 hasPublicationYear "2021" @default.
• W3166128844 type Work @default.
• W3166128844 sameAs 3166128844 @default.
• W3166128844 citedByCount "0" @default.
• W3166128844 crossrefType "journal-article" @default.
• W3166128844 hasAuthorship W3166128844A5006585307 @default.
• W3166128844 hasAuthorship W3166128844A5045006845 @default.
• W3166128844 hasAuthorship W3166128844A5064053465 @default.
• W3166128844 hasAuthorship W3166128844A5070454355 @default.
• W3166128844 hasAuthorship W3166128844A5072346965 @default.
• W3166128844 hasAuthorship W3166128844A5073885025 @default.
• W3166128844 hasAuthorship W3166128844A5089042997 @default.
• W3166128844 hasConcept C121608353 @default.
• W3166128844 hasConcept C126322002 @default.
• W3166128844 hasConcept C143998085 @default.
• W3166128844 hasConcept C2776256026 @default.
• W3166128844 hasConcept C2776694085 @default.
• W3166128844 hasConcept C2777701055 @default.
• W3166128844 hasConcept C2778336483 @default.
• W3166128844 hasConcept C2780057760 @default.
• W3166128844 hasConcept C2780739268 @default.
• W3166128844 hasConcept C2781413609 @default.
• W3166128844 hasConcept C71924100 @default.
• W3166128844 hasConcept C90924648 @default.
• W3166128844 hasConceptScore W3166128844C121608353 @default.
• W3166128844 hasConceptScore W3166128844C126322002 @default.
• W3166128844 hasConceptScore W3166128844C143998085 @default.
• W3166128844 hasConceptScore W3166128844C2776256026 @default.
• W3166128844 hasConceptScore W3166128844C2776694085 @default.
• W3166128844 hasConceptScore W3166128844C2777701055 @default.
• W3166128844 hasConceptScore W3166128844C2778336483 @default.
• W3166128844 hasConceptScore W3166128844C2780057760 @default.
• W3166128844 hasConceptScore W3166128844C2780739268 @default.
• W3166128844 hasConceptScore W3166128844C2781413609 @default.
• W3166128844 hasConceptScore W3166128844C71924100 @default.
• W3166128844 hasConceptScore W3166128844C90924648 @default.
• W3166128844 hasIssue "15_suppl" @default.
• W3166128844 hasLocation W31661288441 @default.
• W3166128844 hasOpenAccess W3166128844 @default.
• W3166128844 hasPrimaryLocation W31661288441 @default.
• W3166128844 hasRelatedWork W2091720821 @default.
• W3166128844 hasRelatedWork W2388730008 @default.
• W3166128844 hasRelatedWork W2396374069 @default.
• W3166128844 hasRelatedWork W2786497694 @default.
• W3166128844 hasRelatedWork W3137670083 @default.
• W3166128844 hasRelatedWork W3215044659 @default.
• W3166128844 hasRelatedWork W3215662100 @default.
• W3166128844 hasRelatedWork W4224862170 @default.
• W3166128844 hasRelatedWork W4312129293 @default.
• W3166128844 hasRelatedWork W4317566941 @default.
• W3166128844 hasVolume "39" @default.
• W3166128844 isParatext "false" @default.
• W3166128844 isRetracted "false" @default.
• W3166128844 magId "3166128844" @default.
• W3166128844 workType "article" @default.